Full Course Description

Lipid Logic: An Update on Current and Future Pharmacologic Approaches to Dyslipidemia Management

Dyslipidemia management requires a multifaceted approach that includes both lifestyle modifications and pharmacotherapy. The primary goal of treatment is to reduce LDL-C levels to lower cardiovascular (CV) risk. Additionally, some patients may require other therapies to address residual CV risk associated with elevated triglycerides or elevated lipoprotein(a) [Lp(a)].

The 2018 AHA/ACC/Multisociety cholesterol guideline emphasized the importance of lowering LDL-C as the primary treatment target. This guideline focuses on populations where statin therapy has been proven to lower both LDL-C and CV event risk, known as the four statin benefit groups. In 2022, the ACC published an Expert Consensus Decision Pathway for nonstatin therapy, recommending specific LDL-C thresholds for all four statin benefit groups, rather than just two as per the 2018 guideline. While statin therapy is effective in reducing CV risk and LDL-C levels, some patients may require additional nonstatin therapies to achieve optimal LDL-C reduction. Several nonstatin therapies, including ezetimibe, bempedoic acid, PCSK9 monoclonal antibodies, and inclisiran, are available and effective in further lowering LDL-C. This program will review these LDL-C lowering therapies and their optimal use to improve patient outcomes.

Even when LDL-C is reduced to recommended levels, patients with elevated triglycerides or Lp(a) remain at increased risk for CV events. Clinicians should be aware of the evidence linking elevated triglycerides and Lp(a) with CV events, as well as the latest innovations and outcomes data related to current and emerging drug therapies for these conditions. This session will review outcomes data on the use of omega-3 fatty acids in patients with elevated triglycerides. Additionally, it will cover two medications in phase III trials, pelacarsen and olpasiran, which lower Lp(a) in conjunction with statin therapy.

Program Information

Objectives

Evaluate the 2018 AHA/ACC/Multisociety cholesterol guideline and 2022 ACC Expert Consensus Decision Pathway on nonstatin therapy recommendations.
Compare the mechanisms of action, efficacy, and outcomes data for currently approved and emerging drug therapies for LDL-C lowering.
Determine recommended treatments for patients with elevated triglycerides according to the 2021 ACC Expert Consensus Decision Pathway on hypertriglyceridemia.
Analyze novel and emerging medications for LDL-C lowering and Lp(a) lowering.

Outline

LDL-C Lowering

Expert consensus recommendations

2018 AHA/ACC/Multisociety Cholesterol Guidelines
2022 ACC Expert Consensus Decision Pathway on nonstatins

Pharmacotherapy options

Statins
Ezetimibe
Bempedoic acid
PCSK9 monoclonal antibodies
Inclisiran

Triglyceride Lowering

2021 ACC Expert Consensus Decision Pathway on hypertriglyceridemia
Pharmacotherapy options

Fibric acid derivatives
Omega-3 fatty acids

Lp(a)

What is Lp(a)
Effect of approved LDL-C lowering medications on Lp(a)
Emerging pharmacotherapies

Pelacarsen
Olpasiran

Target Audience

Physicians
Physician Assistants
Nurses

Copyright : 12/12/2024

Management of Atrial Fibrillation

The American College of Cardiology/American Heart Association/American College of Clinical Pharmacy/Heart Rhythm Society released a new updated guideline for the diagnosis and management of atrial fibrillation (AF) at the end of 2023. The previous classification of AF was based on arrhythmia duration which highlighted AF after it was diagnosed. The guideline also emphasizes the importance of early rhythm control. Some patients develop AF during surgery or acute illness, and the guideline provides recommendations for the management of these patients. Patients with AF have an increased risk of stroke. There are various thromboembolism prevention strategies. The use of wearable devices has increased and can lead to a diagnosis of AF.

When caring for a patient with AF, deciding between rate control or rhythm control is important but can change over time and involves shared decision making. Both are reasonable strategies and based on several factors. There are pharmacological options as well as non-pharmacological options. Specific patient groups require additional considerations when deciding on treatment options. Considerable progress has been made in the prevention and management of AF in recent years.

Program Information

Objectives

Incorporate the newly released classification of atrial fibrillation into practice.
Determine thromboembolism prevention strategies.
Evaluate pharmacology and non-pharmacology options for a rate control strategy.
Analyze pharmacology and non-pharmacology options for a rhythm control strategy.
Review additional considerations for specific patient groups with atrial fibrillation.

Outline

Atrial fibrillation classification
Mechanisms and pathophysiology
Clinical evaluation
Lifestyle and risk factor modification

Primary prevention
Secondary prevention

Thromboembolism prevention

Pharmacological

Anticoagulants
Reversal agents

Nonpharmacological

Percutaneous LAA occlusion device
Cardiac surgery

AHRE
Periprocedural management
Special populations

Rate control strategy

Pharmacological treatment
Nonpharmacological treatment

Rhythm control strategy

Cardioversion

Electrical
Pharmacological

Antiarrhythmic drugs
Catheter ablation
Surgical ablation
Role of pacemakers and ICDs

Special patient groups
Patient education

Target Audience

Physicians
Physician Assistants
Nurses

Copyright : 12/13/2024

Revolution in Diabetes Care

Diabetes management is evolving rapidly, with new medications, updated guidelines, and innovative approaches to optimizing glycemic control while minimizing complications. This one-hour session will explore the latest updates in pharmacologic treatment for diabetes, providing a comprehensive review of the nine major classes of diabetes medications, their mechanisms of action, and key clinical considerations.

Through an engaging lecture and interactive case study, gain practical insights into selecting the most effective treatments based on individual patient needs. Whether managing type 1 or type 2 diabetes, take away the knowledge to implement evidence-based strategies for improved patient outcomes. Stay ahead of the latest advancements and refine your approach to diabetes pharmacology!

Program Information

Objectives

Evaluate the mechanism of action, benefits, and potential side effects of the nine major classes of current diabetes medications.
Analyze pharmacologic treatment guidelines for diabetes stand the implications for patient care.
Apply updated pharmacologic knowledge to practical diabetes medication decisions.

Outline

Diabetes Medication Classes

Biguanides (Metformin) – First-line therapy, insulin sensitivity
Sulfonylureas (Glipizide, Glyburide, Glimepiride) – Insulin secretion
Meglitinides (Repaglinide, Nateglinide) – Rapid-acting insulin secretion
Thiazolidinediones (Pioglitazone, Rosiglitazone) – Insulin sensitivity, risks
DPP-4 Inhibitors (Sitagliptin, Linagliptin, Saxagliptin) – Incretin effects
GLP-1 Receptor Agonists (Semaglutide, Liraglutide, Dulaglutide) – Weight loss, cardiovascular benefits
SGLT-2 Inhibitors (Empagliflozin, Dapagliflozin, Canagliflozin) – Renal and cardiovascular benefits
Insulin Therapy (Rapid, Basal, Mixed) – Individualizing therapy
Amylin analogues (Pramlintide) – Adjunct therapy for type 1 and type 2

Case Study Application to Practice

Patient scenario with comorbidities, A1C levels, and treatment barriers
Select appropriate pharmacologic interventions
Adjust therapy based on patient response and side effects

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Copyright : 05/16/2025

Adrenal Gland Disorders: Mastering Current Treatment and Understanding Future Trends

Adrenal dysfunction can be classified into primary and secondary forms. Primary adrenal insufficiency, also known as Addison’s disease, occurs when the adrenal glands themselves are damaged and unable to produce sufficient hormones. Secondary adrenal insufficiency, on the other hand, results from a deficiency of adrenocorticotropic hormone (ACTH) from the pituitary gland, which stimulates the adrenal glands to product cortisol. Understanding the causes, symptoms, and treatment options for adrenal dysfunction is essential for healthcare professionals, patients, and caregivers.

Throughout this presentation, Dr. Langois will provide a comprehensive look at adrenal dysfunction, its impact on overall health, and the latest advancements in diagnosis and management, ultimately contributing to improved patient outcomes and quality of life. Numerous case studies will be used throughout this presentation to highlight key takeaways.

Program Information

Objectives

Illustrate three actions of the hypothalamus-pituitary-adrenal axis.
Evaluate the actions of medications used to treat Cushing syndrome.
Compare and contrast current pharmacotherapy options to treat Addison Disease.
Categorize the actions of medications used to treat hyperaldosteronism.
Determine medication selection guidelines to treat pheochromocytoma.

Outline

Cushing Syndrome

Signs and symptoms
Laboratory data
Imaging data
Pharmacotherapy and mechanisms of action
- 11-beta-hydroxylase inhibitor - Osilodrostat
- Somatostatin analogs - Pasireotide
- Adrenal steroid inhibitors – Metyrapone, ketoconazole
- Glucocorticoid receptor antagonist - Mifepristone
- Adrenolytic agents - Mitotane
- Adrenal steroid inhibitor – Metyrapone, etomidate
- Dopamine agonist - Cabergoline
Case study

Addison Disease

Signs and symptoms
Laboratory data
Chest radiogram
CT scan
Pharmacotherapy and mechanisms of action
- Hydrocortisone
- Prednisone
- Dexamethasone
- Fludrocortisone
Case study

Congenital adrenal hyperplasia

Signs and symptoms
Laboratory data
Pharmacotherapy and mechanisms of action
- Corticosteroids
- Fludrocortisone
- Salt supplements
- Anti-androgen
- Growth hormone
Case study

Hyperaldosteronism

Signs and symptoms
Laboratory data
Pharmacotherapy and mechanisms of action
- Eplereone
- Lorundrostatt
Case study

Pheochromocytoma

Signs and symptoms
Laboratory data
Pharmacotherapy and mechanisms of action
- Alpha-blockers – Phenoxybenzamine, Phentolamine, Prazosin
- Beta-blockers – Nadolol, Atenolol, Metoprolol
Case study

Adrenal tumors

Signs and symptoms
Pharmacotherapy and mechanisms of action
- Chemotherapy – Doxorubicin, Cisplatin, Etopdise, Azendra (Iodine 131)
- Adrenolytic agent - Mitotane
Pharmacotherapy if adrenal glands are removed
- Hydrocortisone
- Prednisone
- Dexamethasone

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Copyright : 05/15/2025

Beyond the Prescription: Navigating High-Risk Medications & Geriatric Pharmacology in Clinical Practice

This session will provide a case-based approach to geriatric pharmacology, focusing on high-risk medications, drug interactions, and strategies for improving medication safety in older adults. Using real-world case studies, Kiplee Bell, MD, PA, will integrate clinical decision-making principles with the latest BEERS criteria updates and high-risk drug-disease interactions to equip healthcare providers with practical strategies to optimize medication use in geriatric patients.

Program Information

Objectives

Identify high-risk medications per the BEERS Criteria and their potential consequences in older adults.
Recognize common drug-drug and drug-disease interactions that lead to increased hospitalizations.
Apply clinical reasoning to optimize geriatric medication management using case-based learning.
Implement deprescribing strategies and medication reconciliation tools to reduce polypharmacy risks.
Enhance interdisciplinary collaboration to improve patient outcomes.

Outline

The Complexity of Geriatric Medication Management

Polypharmacy and its impact on geriatric patients
Age-related pharmacokinetic and pharmacodynamic changes
Interdisciplinary collaboration in medication safety

Case Review #1: The Hidden Risks of Drug Interactions

Case scenario: An 82-year-old female with multiple chronic conditions presents with increasing confusion, falls, and dizziness after a recent hospitalization
Discussion topics:
- Common drug-drug interactions in geriatrics
- Over-the-counter medications and their unintended effects (NSAIDs, antihistamines, supplements)
- Strategies to deprescribe and optimize therapy

High-Risk Medications in Geriatrics: The BEERS Criteria & Beyond

BEERS criteria: Identify medications that should be avoided, used with caution, or reconsidered
STOPP/START criteria as a tool to reduce inappropriate prescribing
Case-based review
Anticholinergics and cognitive decline
Benzodiazepines, opioids, and fall risk
NSAIDs and risks in chronic kidney disease and heart failure

Case Review #2: High-Risk Drug-Disease Interactions & Deprescribing Strategies

Case scenario: A 76-year-old male with heart failure, diabetes, and chronic kidney disease experiencing uncontrolled blood pressure and fluid retention
Discussion topics:
- High-risk drug-disease interactions in conditions such as diabetes, dementia, renal impairment, and cardiovascular disease
- Strategies for medication reconciliation and deprescribing
- Implement interdisciplinary medication review processes

The Future of Geriatric Pharmacology: Practical Takeaways for Clinical Practice

Best practices for medication reconciliation and patient education
Tools and resources for medication safety assessments
The impact of telehealth and remote monitoring on medication adherence

Target Audience

Registered Nurses
Nurse Practitioners
Physicians
Physician Assistants
Physical Therapists
Physical Therapist Assistants
Occupational Therapists
Occupational Therapy Assistants
Speech Language Pathologists
Social Workers
Counselors
Nursing Home Administrators

Copyright : 10/16/2025

Geriatric Psychopharmacology

Join Steven Rubin, MD, to expand your existing knowledge about medications and their effects on older adults. This presentation will delve into current indications for commonly prescribed medications. There are risks and benefits to weigh when prescribing for our geriatric patients. Some medications will help, while others will hinder. The latest evidence-based pharmaceutical guidelines will be provided, including when to withhold and withdraw medications. Master the skills to integrate modern pharmaceutical knowledge with more traditional prescriptive methods to help patients achieve longevity with quality.

Program Information

Objectives

Recognize fundamental properties and categories of medications and their effects on older adults.
Apply bio-psycho-social medicine insights to the art of caregiving.
Integrate modern pharmaceutical knowledge with traditional prescriptive methods to help patients achieve longevity with quality.
Evaluate current guidelines for patients who may be using both prescription and non-prescription pharmaceutical agents.

Outline

Geriatric Presentations: Drugs, Dementia, Delirium, and other D’s

Disorders of mood: Depression, anxiety and bipolar
Dementia and mild cognitive impairment
Delusions, delirium and (sun)downers

Medications That Help, Medications That Hinder

Risks, benefits & alternatives
Duplicities, triplicities, and specialized care

The Latest Evidence-Based Geriatric Psychopharmacology Guidelines

Prescription considerations
Medications, malpractice, and you (4 more D’s)

Target Audience

Registered Nurses
Nurse Practitioners
Clinical Nurse Specialists
Physician Assistants
Physical Therapists
Physical Thearpist Assistants
Occupational Therapists
Occupational Thearpist Assistants
Speech-Language Pathologists
Social Workers
Counselors
Nursing Home Administrators

Copyright : 03/22/2024

The Crucial Role of Lab Monitoring for Common Geriatric Medications

The primary objectives of medication laboratory monitoring in the elderly are to ensure the safety and efficacy of pharmacological treatments, minimize adverse drug reactions, and optimize therapeutic outcomes. Additionally, monitoring aims to individualize medication regimens by adjusting dosages based on lab results, thus promoting personalized medicine. By closely observing these parameters, healthcare providers can make informed decisions that enhance the quality of life for elderly patients, prevent complications, and support overall health and wellbeing.

Program Information

Objectives

Evaluate current laboratory monitoring recommendations for commonly used medications in the elderly.
Recognize medications that may impact laboratory measurements.
Explain strategies for appropriate laboratory timing.
Determine important drug interactions that may affect laboratory parameters.

Outline

Lab Monitoring for Common Medications Used in the Elderly

Cardiovascular medications
Psychiatric medications
Analgesics
Miscellaneous agents

Medications that May impact Laboratory Measurements

Thyroid toxicity
Liver toxicity
Renal toxicity
Hyper/hypoglycemia
Vitamin B12 deficiency
Anemia/CBC

Strategies for Appropriate Laboratory Timing

Frequency of routine timing
Clinical Indications

Target Audience

Nurses
Nurse Practitioners
Clinical Nurse Specialists
Physician Assistants
Physical Therapists
Physical Therapist Assistants
Occupational Therapists
Occupational Therapy Assistants
Speech-Language Pathologists
Social Workers
Physicians

Copyright : 09/26/2024

Realize the Potential of Rapid-Acting Treatments for Depression

Optimal management of depression begins with adequate screening and early introduction of appropriate therapy. Monoaminergic antidepressants, which are currently considered the standard of care, have several limitations, including low therapeutic response rates, suboptimal efficacy and remission rates, and adverse effects that may impact patient adherence. Josh Hamilton, DNP, APRN-BC, CTMH, CNE, CLNC, FAANP will explore novel pathways involved in the etiology of depression, including glutamatergic and GABAergic modulation. Discover when newer pharmacologic agents, including neuroactive steroids and glutamatergic antidepressants are appropriate. Take away practical prescriptive considerations and apply them to real-world cases.

Program Information

Objectives

Advance your understanding of the mechanisms of action for novel rapid-acting pharmacotherapies for depression.
Evaluate the efficacy and unique safety profiles associated with novel antidepressants.
Select appropriate patients for treatment with rapid-acting antidepressants.
Explain the skills needed to engage in shared decision making to optimize patient outcomes.

Outline

Novel Rapid-Acting Pharmacotherapies for Depression: Mechanisms of Action

Treatment-as-usual
Unmet needs
MDA receptor antagonists
Neuroactive steroid GABA-A modulators

Efficacy and Unique Safety Profiles Associated with Novel Antidepressants

Neurobiology of depression, revisited (GABA/glutamate)
Clinical studies and outcomes

Select Appropriate Patients for Treatment with Rapid-Acting Antidepressants

Case applications
TRD/anhedonia
PPD
Suicidality

Shared Decision Making to Optimize Patient Outcomes

Shared decision-making with patients
Case applications, continued

Target Audience

Nurse Practitioners
Nurses
Physician Assistants
Physicians
Pharmacists

Copyright : 10/25/2024

Psychopharmacology of ADHD

Stephanie Shafer, MSN, ANP-BC, PMHNP-BC, will deliver an advanced and updated review of stimulant (e.g., methylphenidate, amphetamines) and non-stimulant (e.g., atomoxetine, guanfacine) medications, with a particular focus on understanding the mechanisms of action, how they differ, and how one might synergistically compliment another. Learn how these medications affect the brain’s chemistry and function to alleviate ADHD symptoms, allowing for a deeper appreciation of their therapeutic potential. Central to the discussion will be the identification of presenting symptomatology and the evaluating of treatment outcomes. This focus will provide the knowledge and skills needed to adeptly navigate the evolving landscape of ADHD management.

By the talk’s conclusion, you will possess a robust understanding of ADHD’s neurobiological basis, as well as a comprehensive knowledge of the mechanisms by which available medications act. Deliver personalizing care for patients with ADHD to enhance their quality of life and daily functioning to the future.

Program Information

Objectives

Explain the key neurobiological factors involved in ADHD, including neurotransmitter systems, brain regions implicated, and how they contribute to the symptoms of the disorder.
Evaluate the pharmacological treatments available for ADHD, including stimulant medications (e.g., methylphenidate, amphetamines) and non-stimulant mediations (e.g., atomoxetine, guanfacine).
Differentiate ADHD from common differentials and tailor pharmacotherapy to individual patients.
Analyze the effectiveness of ADHD medications, while also considering potential side effects.

Outline

Neurobiology of ADHD

Neurotransmitter systems
Brain regions implicated
Contribution to symptoms

Examine Pharmacological Treatment Options

Stimulant medications
- Methylphenidate
- Amphetamines
Non-stimulant medications
- Atomoxetine
- Guanfacine, etc.
Mechanisms of action
Efficacy and effectiveness
Differences and combinations

Individualized Treatment Strategies

Differential diagnosis
- Distinguish ADHD from common differentials
- Consideration of comorbid psychiatric conditions
Tailoring pharmacotherapy
- Customize treatment plans based on individual patient profiles
- Adjust dosage and medication type as needed
Address overlapping symptomatology
- Strategies to manage symptoms that overlap with other disorders
- Coordinate care with other healthcare providers

Evaluate Treatment Outcomes & Side Effects

Effectiveness of Medications
- Reduction of ADHD symptoms
- Improvement in daily functioning
- Cognitive and emotional beliefs
Side Effects
- Common side effects of ADHD medications
- Strategies to minimize side effects

Copyright : 03/21/2024

GERD, Dyspepsia and Barrett’s Esophagus: Treatment Updates for 2025

Please join Dr. Peter Burch, a double certified clinical gastroenterologist with over 30 years of specialty experience, to explore GERD in a practical, case based, and interaction session. He will provide the highlights on alarm signs with GERD, medical mimickers of GERD, making the correct diagnosis of GERD, clinical differences between PPIs, and discussion on Vonoprazan as a PPI alternative.

At the conclusion of the training, you will have the necessary clinical updates and tools to confidently manage patient with GERD, dyspepsia, and Barrett’s esophagus.

Program Information

Objectives

Evaluate medical mimickers of GERD to make the right clinical diagnosis.
Compare the clinical differences between PPIs.
Discuss Vonoprazan as a PPI alternative.
Plan to incorporate updates and tools to confidently manage patients with GERD, dyspepsia, and Barrett’s esophagus.

Outline

GERD

How to make the diagnosis of GERD
Factors that increase GERD
Unusual manifestations of GERD
PPI efficacy for unusual manifestations
Foods and meds that exacerbate GERD
Complications of GERD

Dyspepsia as a mimicker of GERD

Define dyspepsia/functional dyspepsia
How to distinguish dyspepsia/functional dyspepsia from GERD

Alarm “Signs” and GERD

Gastroparesis as a Mimicker of GERD

Etiologies and treatment of gastroparesis

Achalasia as a Mimicker of GERD

Treatment of achalasia

PPIs

Are there clinical differences among PPIs?
”Tachyphylaxis”
PPI overuse

PPI Side Effects Discussion

Reality vs observational data
How to “de prescribe” PPIs
Reasons to continue PPIs

Vonoprazan

The new kid on the block
Benefits over PPIs

Barrett’s esophagus

Risk factors: Which women should be screened for Barrett’s
Cancer risk
Limitations of endoscopy
- Accuracy of current guidelines to detect Ca
Do PPIs & NSAIDS prevent progression of Barrett’s to cancer
How to manage low grade dysplasia
Does Barrett’s ever disappear
What age should we stop Barret’s surveillance

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Copyright : 05/15/2025

Necessary Medication Adjustments in Patients with Kidney Failure

In the United States, chronic kidney disease is very common. Patients who have chronic kidney disease typically also have a number of other co-morbid conditions. As a result, these patients typically take more than one medication for the management of their chronic condition, which may include medications for high blood pressure, diabetes, and other conditions. Because of the decline in kidney function, the dosages of the medications used to treat these chronic conditions need to be carefully adjusted in order to prevent adverse drug reactions. In addition, it is important to note that patients who have advanced chronic kidney disease should not take certain medications. It is essential for primary care providers to have an understanding of the various stages of chronic kidney disease and the ability to adjust medications based on how well the kidneys are functioning. In addition to this, it is essential you correctly diagnose patients who have drug interactions and toxicities, particularly those patients whose kidney function is compromised.

Program Information

Objectives

Analyze progression of chronic kidney disease to end-stage kidney disease.
Manage medication related problems in kidney failure.
Determine risk factors for medication related problems in kidney failure.
Evaluate the adverse drug reactions of nephrotoxic medications.

Outline

Chronic kidney disease progression to end-stage kidney disease

Medication related problem in kidney failure

Blood pressure medication in kidney failure patients
Volume management in kidney failure patients
Diabetic medications in kidney failure patients
Anemia issues in kidney failure patients
Metabolic bone disease management in kidney failure patients
Pain management in kidney failure patients

Risk factors for medication related problems in patients with kidney failure

Case Study

Copyright : 03/22/2024

Antimicrobial Updates for Primary Care: A Pharmacotherapy Focus

This engaging and practical session, “Antimicrobial Updates for Primary Care: A Pharmacotherapy Focus,” led by Dr. Eric Wombwell, a board-certified infectious disease pharmacist and clinical professor, will provide practitioners with the latest evidence-based strategies for managing common infectious diseases in the primary care setting. The presentation will delve into critical updates regarding penicillin allergies, differentiating true allergies from intolerances to ensure appropriate beta-lactam use. Dr. Wombwell will also review current treatment guidelines for community-acquired pneumonia, considering comorbidities and antibiotic resistance, and provide a review of Clostridioides difficile infection, including the use of recently approved fecal microbiota products.

A significant portion of the session will be dedicated to urinary tract infections, covering first-line treatment options, the increasing role of fosfomycin and nitrofurantoin in the face of evolving resistance trends, new antibiotic approvals, and emerging guidance from WikiGuidelines and anticipated IDSA recommendations. The session will also address skin infections, including appropriate antibiotic choices and MRSA coverage, and recap the 2023 diabetic foot infection recommendations. Through case-based discussions and practical application of current guidelines, participants will enhance their ability to optimize antimicrobial prescribing, minimize adverse effects, and contribute to antimicrobial stewardship efforts.

Program Information

Objectives

Apply appropriate strategies for antibiotic selection in patients with reported penicillin allergies, minimizing unnecessary avoidance of beta-lactam antibiotics.
Synthesize recent data on UTI treatment, including resistance trends, new antibiotic approvals, and emerging consensus guidelines to optimize patient care.
Choose effective antibiotic therapies that minimize risk for adverse effects.
Implement strategies to optimize antimicrobial prescribing, contributing to antimicrobial stewardship efforts and minimizing the development of resistance.

Outline

Penicillin Allergies

Manage patients with antibiotic allergies
Distinguish between true allergies and intolerances

Community-Acquired Pneumonia

Current treatment guidelines
Considerations for comorbidities and antibiotic resistance

Clostridioides Difficile Infection

Up-to-date guidelines for pharmacological treatments
Considerations for recently approved fecal microbiota products

Urinary Tract Infections

Fist-line treatment options, including considerations for local resistance patterns
Increase role of fosfomycin and nitrofurantoin
Recent resistance trends
New antibiotic approvals
Highlight WikiGuidelines Group Consensus guidance and expected IDSA recommendations

Skin Infections

Appropriate antibiotic choices, including coverage for MRSA when indicated
Recap on the 2023 Diabetic Foot Infection recommendations

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Copyright : 05/15/2025

Wound Care Pharmacology: Enhancing Healing Outcomes

M. Dolores Farrer, DPM, MBA, CWS®, will explore the critical role of pharmacological treatments in promoting the healing of both acute and chronic wounds. You will gain a comprehensive understanding of the various products and therapies used in wound care, as well as the underlying mechanisms that drive the healing process.

Wound care pharmacology encompasses a wide range of treatments designed to manage and treat wounds effectively. These treatments include wound irrigation, antiseptics, topical skin adhesives, hemostasis agents, and specialized therapies for severe burns and diabetic ulcers. Each of these products plays a vital role in preventing infection, promoting clot formation, and facilitating the healing of damaged tissues.

In the context of chronic wounds, such as diabetic ulcers, venous leg ulcers, and pressure ulcers, pharmacological treatments are particularly crucial. Chronic wounds often have prolonged healing times and are susceptible to infections and microbial biofilm formation. The healing process involves several phases, including inflammation, proliferation, and remodeling. Pharmacological treatments aim to manage these phases effectively by addressing the underlying causes and promoting the natural healing process.

During this session, we will delve into various pharmacological treatments used in chronic wound care. These include antimicrobial agents to prevent and treat infections, growth factors to stimulate cell proliferation and tissue regeneration, and negative pressure wound therapy (NPWT) to promote blood flow and tissue formation. You will have an opportunity to explore emerging treatments such as stem cell therapy, which holds promise for promoting tissue regeneration and repair.

Additionally, use of anti-inflammatory agents will be covered, to reduce prolonged inflammation in chronic wounds and advanced dressings that provide a moist environment, deliver medications, and protect the wound from further injury. By addressing the specific needs of chronic wounds, these pharmacological treatments can significantly improve healing outcomes and reduce the risk of complications.

You will gain valuable insight into the field of wound care pharmacology and the knowledge and tools needed to enhance patient outcomes.

Program Information

Objectives

Gain a comprehensive understanding of how pharmacological treatments are used to promote the healing of both acute and chronic wounds.
Analyze specific pharmacological treatments used in chronic would care, including antimicrobial agents, growth factors, negative pressure wound therapy (NPWT), stem cell therapy, anti-inflammatory agents, and advanced dressings.

Outline

Phases of Wound Healing

Hemostasis
Inflammation
Proliferation
Remodeling

Pharmacological Treatments for Acute Wounds

Wound irrigation
Antiseptics
Topical skin adhesives
Hemostasis agents

Pharmacological Treatments for Chronic Wounds

Antimicrobial agents
Growth factors
Negative pressure wound therapy (NPWT)
Stem cell therapy
Anti-inflammatory agents
Advanced dressings

Emerging Treatments and Innovations

New developments in wound care pharmacology
Future directions and research

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Copyright : 05/16/2025

Orthopedic Pharmacology and Perioperative Management

You will deepen your understanding and proficiency in prescribing a wide array of medications tailored for patients with orthopedic injuries and conditions. The focus will be on a holistic approach to orthopedic pharmacotherapy, encompassing the use of corticosteroids, both oral and injectable, alongside an exploration of other innovative injection therapies. You will also delve into the world of antirheumatic medications, understanding their role in managing autoimmune and inflammatory components of orthopedic diseases.

The session will also shed light on the strategic use of antidepressants and antiepileptics in the context of orthopedic pain management, highlighting their dual role in addressing chronic pain and enhancing quality of life. Over-the-counter medication strategies will also be examined for their accessibility and efficacy in providing symptomatic relief. Finally, perioperative management will be discussed, equipping attendees with the knowledge to optimize medication regimens before orthopedic surgical procedures to improve outcomes and ensure patient safety. Through interactive lecture-based content, case studies, and evidence-based reviews, this session promises to empower healthcare professionals with the tools and confidence needed to navigate the complex landscape of orthopedic prescribing.

Program Information

Objectives

Evaluate the role and use of corticosteroids, injections, and other pain alternatives in treating orthopedic pain.
Analyze the current guidelines and literature to support decision making process in medication selection.
Incorporate perioperative management recommendations for common orthopedic procedures.
Design a treatment plan for various patient encounters related to orthopedic injuries and perioperative management.

Outline

Mastering Orthopedic Pain Management Medications (Non-Opioids)

Corticosteroids (oral and injectable)
Other injection options
DMARDS
Antidepressants
Antiepileptics
Over-the-counter medications

The Potion for Motion: Appropriate Medication Selection

Specific considerations for appropriate selection of alternatives to common pain medications
Shared decision making and counseling on potential side effects and interactions
Review strategies for encouraging patient adherence

Operation Preparation: Perioperative Recommendations

Medication guidelines and classes that are often held prior to orthopedic procedures
Specific recommendations and considerations for length of pause

Application

Create treatment plans for patient cases related to orthopedic pain management

Provide recommendations for perioperative management

Copyright : 05/21/2024

Pain and Non-Pain Symptom Management in Serious Illness: Steps for Drug Therapy Selection

Patients living with a serious illness commonly experience pain and non-pain symptoms. Mary Lynn McPherson, PharmD, PhD, BCPS, FAAHPM, will use a critical thinking process to illustrate the steps in drug therapy selection. Steps include identifying and assessing the problem (including multidimensional assessment and determination of the pathogenesis of symptom report), defining the therapeutic objective and relevant monitoring parameters, considerations in choosing the optimal medication(s), a monitoring plan for possible toxicity, and how to monitor and take action based on the patient’s response to the recommended drug therapy. In addition to pain management, you will discuss nausea and vomiting, anxiety, depression, dyspnea and constipation. Elevate your skills to both assess and manage common physical symptoms in serious illness including pain, and common non-pain symptoms.

Program Information

Objectives

Determine the steps in the drug therapy selection and monitoring process for pain in serious illness.
Differentiate between subjective and objective monitoring parameters for therapeutic effectiveness and potential toxicity.
Evaluate best practice therapeutic approaches to non-pain symptoms in serious illness.
Recommend a pharmacotherapy plan including monitoring for a simulated case of a patient with pain and a non-pain symptom.

Outline

Drug Therapy Selection Process

Problem identification and assessment (including multidimensional assessment)
Define the therapeutic objective
Monitoring parameters for therapeutic effectiveness
Develop list of possible treatment options
Consider patient- and drug-related variables that influence drug selection
Select appropriate pharmacologic agent(s)
Monitoring parameters for potential toxicity
Implement recommendation
Monitor patient’s response to drug therapy
Adjust pharmacotherapy regimen as indicated

Pain Report Case Application

Fifty-four year old woman with stage 4 breast cancer with mediastinal, right axillary node, and bone (rib) metastases
Soft tissue and lymph node metastases in the right axilla, as well as an esophageal stricture from tumor in mediastinum
Pain in four separate locations
- Assess each pain report (multidimensional pain assessment)
- Conclude pathogenesis of each pain report
- Apply drug therapy selection process – all steps
Non-Pain Symptom Management
- Common non-pain physical symptoms associated with serious illness (e.g., nausea, anxiety, depression, dyspnea, constipation)
- Recommend pharmacologic and non-pharmacologic treatment strategies for each

Target Audience

Social Workers
Nurses
Physicians

Copyright : 11/15/2024

Hormone Replacement Therapy Risks & Benefits: Current Guidelines and Recommendations for Female Patients

Hormone Replacement Therapy (HRT) has long been a topic of interest and debate in the management of menopausal symptoms, particularly vasomotor symptoms such as hot flashes and night sweats. Deidre Arms, MSN, APRN, CNP will provide a comprehensive overview of HRT, focusing on the effectiveness in alleviating vasomotor symptoms and improving the quality of life for menopausal women. You will gain insights into the physiological mechanisms underlying vasomotor symptoms and how HRT mitigates these effects.

Explore the various forms of HRT available, their respective advantages and drawbacks, and the importance of personalized treatment plans. The session will also address the potential risks associated with HRT, and how to balance these risks against the benefits. Current guidelines and recommendations from leading health organizations will be reviewed to aid in clinical decision-making. The discussion will also include alternative and complementary therapies for patients who cannot or choose not to use HRT.

Program Information

Objectives

Evaluate vasomotor symptoms and their prevalence in menopausal women.
Explain the mechanism of action of hormone replacement therapy (HRT) in managing vasomotor symptoms.
Analyze the benefits and risks associated with HRT.
Plan to incorporate current guidelines and recommendations for the use of HRT in menopausal women.

Outline

Hormone Replacement Therapy (HRT)

Types of HRT (estrogen-only, combined estrogen-progestogen)
Mechanism of action in alleviating vasomotor symptoms
Forms of HRT (oral, transdermal, topical, vaginal)

Benefits of HRT

Relieve of vasomotor symptoms
Additional benefits (bone health, potential cardiovascular benefits)

Risks and Considerations

Potential risks (cancer, cardiovascular risks, side effects)
Balancing risks and benefits
Contraindications and alternative treatments

Guidelines and Recommendations

Current guidelines from major health organizations
Criteria for patient selection
Monitoring and follow-up

alternative and Complementary Therapies

Non-hormonal treatments (SSRIs, SNRIs, gabapentin, clonidine)
Lifestyle modifications (diet, exercise, stress management)
Complementary therapies (herbal supplements, acupuncture, mindfulness)

Target Audience

Nurse Practitioners
Nurses
Physician Assistants
Physicians
Pharmacists

Tailoring Cardiovascular Care for Women

The course objective is to review the current state of women’s cardiovascular (CV) health and how traditional and non-traditional CV risk factors impact women’s CV risk across the life span. The course will also help to gain a better understanding of the presentations and mechanisms of ischemia in women and examine how we can tailor cardiovascular practice to incorporate sex-specific considerations to enhance women’s CV health and well-being.

Program Information

Objectives

Review the current state of women’s cardiovascular (CV) health.
Evaluate how traditional and non-traditional CV risk factors impact women’s CV risk across the life span.
Unlock a current understanding of the presentations and mechanisms of ischemia in women.
Examine how we can tailor cardiovascular practice to incorporate sex-specific considerations to enhance women’s CV health and well-being.

Outline

The current state of American women’s cardiovascular (CV health)
How traditional and non-traditional CV risk factors impact women’s CV risk throughout their lifespan
Tailoring CV practices to incorporate sex-specific considerations
Address care delivery inequities to enhance women’s CV health and well-being

Target Audience

Nurse Practitioners
Nurses
Physician Assistants
Physicians
Pharmacists

Beyond the Blue Pill: Pharmacologic & Whole Person Care Strategies to Treat ED

Erectile dysfunction (ED) is more than just a quality-of-life issue – it is a clinical symptom for underlying vascular, metabolic dysfunction, and mental health status. This session will equip you with the knowledge to approach ED not just as a symptom to treat, but as an opportunity to intervene early on cardiometabolic risk factors.

Lara Zakaria PharmD, MS, CNS, CDN, IFMCP is a pharmacist and professor, with 20 years’ experience in community pharmacy. She will explore cornerstone pharmacologic options, including PDE-5 inhibitors and testosterone therapy, while integrating broader strategies such as dietary interventions, exercise, and evidence-based nutraceuticals.

By reframing ED as a systemic health indicator rather than an isolated condition, this session will equip practitioners with practical tools to optimize treatment outcomes, enhance patient counseling, and implementing a whole-person care approach that addresses both immediate symptoms and long-term health risks.

Program Information

Objectives

Evaluate the pathophysiology of erectile dysfunction and its role as an early indicator of cardiovascular and metabolic disease risk.
Apply evidence-based pharmacologic and integrative treatment strategies for erectile dysfunction, considering both patient safety and long-term health outcomes.

Outline

Reframing Erectile Dysfunction (ED) as a Clinical Red Flag

ED as a predictor of vascular and metabolic disease: Cardiovascular disease, hypertension, type 2 diabetes, and chronic kidney disease
Early marker for endothelial dysfunction and systemic inflammation
Psychological and hormonal considerations
- Anxiety, depression, and stress-related contributors
- The role of testosterone and when to investigate hypogonadism

Pathophysiology of ED: Why it Happens Matters for Treatment

Vascular causes: Atherosclerosis, endothelial dysfunction, impaired nitric oxide production
Neurogenic causes: Diabetes-related neuropathy, spinal cord injury, post-surgical complications
Endocrine causes: Testosterone deficiency, metabolic syndrome, thyroid dysfunction
Psychogenic ED: Stress, anxiety, performance-related concerns
Medication-induced ED: Common culprits (SSRIs, beta-blockers, thiazide diuretics, opioids, etc.)

Pharmacologic Treatment Strategies: Choosing the Right Approach

PDE-5 Inhibitors: Sildenafil, tadalafil, vardenafil, avanafil
- Mechanism of action, efficacy, and duration differences
- Safety considerations (CF risks, contraindications with nitrates, hypotension risk)
- Common side effects and patient counseling points
Testosterone therapy: When (and When NOT) to prescribe
- Indications for TRT: Diagnosing hypogonadism vs. age-related testosterone decline
- Risks: Polycythemia, prostate cancer concerns, CV risk controversy
- Monitoring guidelines: hematocrit, PSA, lipid panels, symptom improvement
Alternative pharmacologic options
- Intracavernosal injections (alprostadil)
- Vacuum erection devices
- Off-label options (e.g., dopamine agonists, centrally acting agents)

The Integrative Approach: Beyond Medications

Dietary & lifestyle strategies for ED prevention & management
- Mediterranean diet & endothelial health
- Physical activity: Benefits of resistance training& cardiovascular exercise
- Smoking cessation & alcohol moderation
- Sleep optimization for hormonal balance
Herbal & nutraceutical considerations
- L-arginine & nitric oxide production
- Panax ginseng & adaptogens for stress-related ED
- Yohimbine: Risks vs. benefits
- Omega-3s, flavonoids, and polyphenols for vascular support
Stress management & psychosocial interventions
- Cognitive Behavioral Therapy
- Mindfulness-based approaches

Clinical Case Integration: Applying Knowledge to Practice

Patient Case: 56-year old male with ED, prediabetes, mild hypertension
- Initial assessment: Ruling out secondary causes
- Prescribing decision: PDE-5 inhibitor vs. testosterone testing
- Integrative counseling: Cardiometabolic risk reduction, lifestyle modifications

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Anti-Obesity Medication Treatments: Clinical Pearls for Prescribers

Anti-Obesity Medication Treatments: Clinical Pearls for Prescribers explores the pathophysiology of obesity, current FDA-approved anti-obesity medications, and their mechanisms of action to equip providers with the knowledge to select and manage patients with obesity confidently. Ahunna Freeman, PharmD, BCGP, will highlight valuable clinical pearls and include interactive patient cases to optimize patient outcomes in the management of obesity.

Program Information

Objectives

Evaluate the epidemiology and pathophysiology of obesity.
Determine clinical practice guidelines in the management of obesity in adults.
Analyze FDA-approved pharmacologic options for the management of obesity.
Develop appropriate therapeutic approaches for patient cases.

Outline

Epidemiology/Pathophysiology of Obesity

Obesity as a chronic, multifactorial condition with health consequences
Factors that affect or contribute to obesity
Limitations of lifestyle interventions in the management of obesity

Mechanism of Action for Anti-Obesity Medications (AOMs)

Explain the physiology of weight regulation
- Patient: Caloric deficit, physical activity, stress management/psychologically
- Metabolic adaptation: Hormones & metabolism
Treatment guidelines: Non-pharmacological and pharmacological options
Role of AOMs in weight management

Key Medications in the Management of Obesity

Clinical pearls of each FDA-approved AOM:
- Initiating dose and formulations
- Therapeutic strength
- FDA-approved criteria
- Potential adverse effects
- Monitoring plans
- Use in special populations/individualized treatment based on comorbidities
- Use with other medications/potential interactions
- Approximate Cost

Study trial results for the newest class of AOMs for clinical significance

Highlights from current research on AOMs

Target Audience

Nurse Practitioners
Nurses
Physician Assistants
Physicians
Pharmacists

Rash Decisions: Diagnosing and Treating Skin Lesions

Atopic dermatitis and psoriasis can be difficult to treat, new guidelines include biologics as being the standard of therapy due to their efficacy. Other therapies are gaining traction as adjunctive therapy for these dermatological conditions. Treatment guidelines for conditions like atopic dermatitis and psoriasis include a range of options. For atopic dermatitis, treatments involve topicals such as corticosteroids, calcineurin inhibitors, VTAMA, and Opzelura, as well as biologics like Dupixent, Adbry, and Ebglyss, and Jak inhibitors such as Cinbinqo and Rinvoq. Psoriasis is treated with TNF-alpha inhibitors, IL-17 inhibitors, and IL-23 inhibitors. Light therapy is also recognized as an important adjunctive treatment for these conditions.

In addition, over the counter (OTC) medications are commonly used for dermatological issues, and their appropriate application and duration are key in deciding when to seek advanced care. Nonpharmacological treatments such as wound care and skincare routines, including moisturizers, are also significant. Ongoing research is focused on new therapies, with particular attention to biologics for psoriasis and atopic dermatitis. Barriers to treatment include financial concerns, cost-effectiveness, prescription assistance programs, insurance, and myths about biologics. Challenges such as compliance, needle phobia, and uncertainty about treatment efficacy also need consideration, along with the importance of lab monitoring and follow-up care.

Program Information

Objectives

Determine the current pharmacological treatments for plaque psoriasis and atopic dermatitis, including topical therapies, systemic treatments, and biologics.
Explain the role of over-the-counter medications in acute management of dermatological conditions.
Assess monitoring for signs of infection and the importance of appropriate use of antibiotics in conjunction with other therapies.
Discuss non-pharmacological strategies in managing plaque psoriasis and atopic dermatitis, such as skincare routines, moisturizers, and phototherapy.
Evaluate ongoing research and potential future treatments for both atopic dermatitis and plaque psoriasis.
Address common barriers to treatment adherence and strategies to improve long-term management.

Outline

Atopic Dermatitis Current Clinical Treatment Guidelines

Topicals: Topical steroids, Calcinuerin Inhibitors, VTAMA, Opzelura
Biologics (Dupixent, Adbry, Ebglyss)
Jack Inhibitors: Cibinqo, Rinvoq

Psoriasis Current Clinical Treatment Guidelines

TNF-Alpha Inhibitors
IL-17 inhibitors
IL-23 inhibitors

Light therapy as adjunctive treatment for dermatological conditions

Over the Counter Medications

Appropriate use of over-the-counter topical medications for dermatology problems
Duration of OTC therapy before seeking a higher-level of care

Nonpharmacological Management

Wound Care
Moisturizes and skincare routines (combination strategies)

Research

Brand new therapies in the pipeline
Current literature with biologics
- Psoriasis
- Atopic Dermatitis
Barriers
- Financial
  - Cost effectiveness
  - Prescription assistance programs
  - Co-pay assistance cards
  - Insurance
- Fact vs. myth over biologic
- Needle phobia
- Lab monitoring/follow up
- Uncertainty of treatment efficacy

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs

Systemic Lupus Erythematosus: Clinical and Pharmacologic Management

A comprehensive overview of Systemic Lupus Erythematosus (SLE), covering its pathogenesis, epidemiology, and classification criteria. Learners will explore diagnostic techniques, treatment options, and special considerations such as comorbidities and pregnancy. The course also emphasizes a multidisciplinary approach to patient care and highlights valuable community resources and advocacy programs to support patients with SLE.

Program Information

Objectives

Describe the epidemiology and pathogenesis of Systemic Lupus Erythematosus (SLE).
Identify the symptoms and laboratory criteria which support the diagnosis of SLE.
Recognize potential comorbid conditions that may develop in patients with SLE.
Devise practical individualized treatment regimens based on the patient’s clinical assessment and their lab values.
Collaborate with the multidisciplinary healthcare team to address the complex needs of patients with SLE.
Analyze case studies of patients with SLE.
List ways in which the Lupus Foundation can be instrumental in helping patients and families affected by SLE.

Outline

Introduction to Systemic Lupus Erythematosus (SLE):

Definition, Pathogenesis, and Epidemiology
European Alliance of Associations for Rheumatology (EULAR) / American College of Rheumatology (ACR) Classification Criteria
Common Signs and Symptoms

Evaluation and Diagnosis

Medical and Family History
Clinical Assessment Techniques
Laboratory Analysis: Initial and Ongoing Review

Treatment Approaches

Physical and Occupational Therapy
Non-Pharmacologic Strategies
Pharmacologic Treatments (Rx)

Special Considerations

Comorbid Conditions
Pregnancy and SLE

Community Resources and Advocacy

Support Programs and Resources
Advocacy and Patient Support Networks

Target Audience

Nurses
Nurse Practitioners
Clinical Nurse Specialists
Physician Assistants
Physical Therapists
Physical Therapist Assistants

Clinical Pharmacology Research & Practical Applications to Patient Care

Welcome to a discussion on the practical application of key pharmacology statistical markers and their relevance to patient care. After nearly 20 years of clinical practice as a pharmacist/physician, Dr. Richard Harris has discovered that understanding and effectively communicating data to patients are two entirely different challenges. True clinical mastery involves integrating population-based science with the personalized information obtained form individual patients.

In this discussion, we will cover essential concepts such as absolute risk reduction, the number needed to treat, and the number needed to harm, all of which are crucial for shaping patient expectations. We will also explore confidence intervals and how they can be utilized to personalize treatment and set realistic patient expectations. This promises to be an engaging discussion that connects clinical research with real-world patient care.

Program Information

Objectives

Identify the absolute risk reduction and use it to compute the number needed to treat.
Recognize how to apply confidence intervals to clinical practice.

Outline

Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR): What’s the Difference

Where to find this information
How this affects patient care and patient perception

Number Needed to Treat (NNT) and Number Needed to Harm (NNH)

How to calculate these essential numbers
Why NNT and NNH are crucial in prescribing practice
- Mechanism vs. outcomes

Apply Confidence Intervals to Clinical Practice

Wide vs narrow confidence intervals and how you evaluate them

Putting it All Together via the CBR Calculation

Cost/benefit/risk analysis

Target Audience

NPs
APRNs
PAs
PharmDs
MDs
DOs